**AI生物科技新秀CellVoyant完成760万英镑种子轮融资**
源自英国布里斯托大学的AI生物科技初创公司CellVoyant近日宣布，已成功获得760万英镑的种子轮融资，这一消息在业界引发了广泛关注。CellVoyant以其创新的人工智能成像技术，为干细胞疗法的开发商提供了更高效的新疗法制造方案，有望加速生物医疗领域的科技进步。
本次融资由知名投资机构Octopus Ventures领投，显示出投资者对CellVoyant技术潜力的强烈信心。此外，Horizons Ventures、Air Street Capital和Verve Ventures等知名投资方也参与了此次投资，共同助力CellVoyant的发展。
CellVoyant的AI技术在干细胞研究和疗法开发中的应用，为解决传统方法的效率瓶颈提供了新的可能。通过精准的成像分析，该公司能够帮助研究人员更准确地监测和控制干细胞的生长与分化，从而优化疗法的生产过程，降低成本，提高治疗效果。
此次种子轮融资的成功，不仅为CellVoyant的进一步研发和市场拓展提供了资金保障，也标志着AI技术在生物科技领域的深度结合正不断取得新的突破。CellVoyant表示，将利用这笔资金加速技术的商业化进程，同时扩大团队规模，以满足日益增长的市场需求。
CellVoyant的创新模式和强大的投资者阵容，预示着其在未来生物科技市场中将占据一席之地，有望引领一场干细胞疗法研发的新革命。
英语如下：
**AI Biotech Startup CellVoyant Raises £7.6M Seed Funding to Accelerate Stem Cell Therapy Development**
Keywords: AI biotechnology, CellVoyant, seed funding round
**AI biotech newcomer CellVoyant secures £7.6 million seed funding round**
CellVoyant, an AI biotech startup originating from the University of Bristol, has announced that it has successfully closed a £7.6 million seed funding round, drawing significant attention in the industry. The company’s innovative artificial intelligence imaging technology offers a more efficient solution for developers of stem cell therapies, potentially accelerating advancements in the biomedical sector.
The round was led by prominent investor Octopus Ventures, demonstrating strong investor confidence in CellVoyant’s technological potential. Other notable investors, including Horizons Ventures, Air Street Capital, and Verve Ventures, also participated, supporting CellVoyant’s growth.
CellVoyant’s AI technology addresses efficiency challenges in stem cell research and therapy development. By providing precise imaging analysis, the company enables researchers to monitor and control stem cell growth and differentiation more accurately, optimizing therapy production, reducing costs, and enhancing treatment outcomes.
This successful seed funding round not only ensures financial support for CellVoyant’s ongoing research and market expansion but also signifies continuous breakthroughs in the integration of AI technology within the biotech field. The company intends to utilize the funds to hasten the commercialization of its technology and expand its team to cater to increasing market demands.
CellVoyant’s innovative approach, combined with its impressive roster of investors, positions the company for a significant role in the future biotech market and sets the stage for a new revolution in stem cell therapy development.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 1